VHAG in Treating R/R T-ALL/LBL

Acute T cell lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive type of leukemia that results from the malignant evolution of T-lineage progenitor cells at different differentiation stages. After induction chemotherapy and consolidation chemotherapy, there are still about 30% of patients who cannot achieve complete remission of clinical symptoms or negative MRD. This is also an important factor for the recurrence of ALL patients. In addition, most relapsed T-ALL/LBL patients relapse during first-line treatment. Once the disease relapses, it is difficult to cure for most young and adult patients, and the overall survival rate of patients is less than 10%.

NCT Number	NCT06742463
Lead Sponsor	First Affiliated Hospital of Zhejiang University
Conditions	Acute T Lymphpblastic Leukemia/Lymphoma
Enrollment	50 participants
Start Date	2024-12
Primary Completion	2026-06-30 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2024-12-19